Mårtensson G - Search Results

1

Clinical utility of liquid-chromatographic analysis of effusions for hyaluronate content.

Nurminen M, Dejmek A, Mårtensson G, Thylen A, Hjerpe A. Nurminen M, et al. Among authors: martensson g. Clin Chem. 1994 May;40(5):777-80. Clin Chem. 1994. PMID: 8174251

2

The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods.

Martensson G, Thylen A, Lindquist U, Hjerpe A. Martensson G, et al. Cancer. 1994 Mar 1;73(5):1406-10. doi: 10.1002/1097-0142(19940301)73:5<1406::aid-cncr2820730515>3.0.co;2-i. Cancer. 1994. PMID: 8111707 Clinical Trial.

3

Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma.

Thylén A, Hjerpe A, Martensson G. Thylén A, et al. Among authors: martensson g. Cancer. 2001 Sep 1;92(5):1224-30. doi: 10.1002/1097-0142(20010901)92:5<1224::aid-cncr1441>3.0.co;2-u. Cancer. 2001. PMID: 11571736

4

Immunohistochemical differences between hyaluronan- and non-hyaluronan-producing malignant mesothelioma.

Thylén A, Levin-Jacobsen AM, Hjerpe A, Martensson G. Thylén A, et al. Among authors: martensson g. Eur Respir J. 1997 Feb;10(2):404-8. doi: 10.1183/09031936.97.10020404. Eur Respir J. 1997. PMID: 9042640 Free article.

5

Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing malignant mesothelioma.

Thylén A, Wallin J, Martensson G. Thylén A, et al. Among authors: martensson g. Cancer. 1999 Nov 15;86(10):2000-5. Cancer. 1999. PMID: 10570424

6

Ifosfamide in malignant mesothelioma: a phase II study.

Andersen MK, Krarup-Hansen A, Mårtensson G, Winther-Nielsen H, Thylen A, Damgaard K, Olling S, Wallin J. Andersen MK, et al. Among authors: martensson g. Lung Cancer. 1999 Apr;24(1):39-43. doi: 10.1016/s0169-5002(99)00030-6. Lung Cancer. 1999. PMID: 10403693 Clinical Trial.

7

[Malignant mesothelioma. New diagnostic and therapeutic methods make the disease curable].

Hillerdal G, Brodin O, Hjerpe A, Malina J, Mårtensson G, Strander H, Tornling G. Hillerdal G, et al. Among authors: martensson g. Lakartidningen. 1993 Oct 6;90(40):3437-40. Lakartidningen. 1993. PMID: 8231486 Swedish. No abstract available.

8

A phase II study of vincristine in malignant mesothelioma--a negative report.

Mårtensson G, Sörenson S. Mårtensson G, et al. Cancer Chemother Pharmacol. 1989;24(2):133-4. doi: 10.1007/BF00263135. Cancer Chemother Pharmacol. 1989. PMID: 2731313

9

Asbestos pleural effusion: a clinical entity.

Mårtensson G, Hagberg S, Pettersson K, Thiringer G. Mårtensson G, et al. Thorax. 1987 Sep;42(9):646-51. doi: 10.1136/thx.42.9.646. Thorax. 1987. PMID: 3686454 Free PMC article.

10

Radiographic appearance and lung function after non-malignant pleural effusion.

Mårtensson G, Bake B, Brolin I, Larsson S, Pettersson K, Thiringer G. Mårtensson G, et al. Eur J Respir Dis. 1987 Oct;71(4):306-13. Eur J Respir Dis. 1987. PMID: 3691685

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

140 results

Search Page

Filters